S-(-)-ET 126

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: S-(-)-ET 126
• 英文别名: S-(-)-α-(hydroxymethyl)benzeneacetic acid 1-methyl-4-piperidinyl ester；(1-methylpiperidin-4-yl) (2S)-3-hydroxy-2-phenylpropanoate
• 化学式: C₁₅H₂₁NO₃
• 分子量: 263.337
• InChiKey: KHOGRUNVGQDQGJ-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  S-托品酸 在 盐酸 、 氯化亚砜 作用下， 反应 30.5h， 生成 S-(-)-ET 126
  参考文献：
  名称：

  Differential analgesic activity of the enantiomers of atropine derivatives does not correlate with their muscarinic subtype selectivity

  摘要：

  The enantiomers of several tropic and p-substituted tropic acid esters related to atropine obtained by esterification under non-racemizing conditions after resolution of the corresponding racemic acids [(+)- and (-)-18, (+)- and (-)-19] are reported. They were tested in vitro on muscarinic subtype receptors and in vivo for their analgesic activity on mice. As in the case of the lead compound, R-(+)-hyoscyamine, these substances show enantioselectivity in analgesic tests, the eutomers being the R-(+) or R-(+)-p-substituted tropic acid derivatives. However, this property, which is a consequence of increased central release of ACh, seems unrelated to muscarinic subtype selectivity insofar as the compounds are unable to discriminate muscarinic subtype receptors. A possible explanation of these results which does not involve subtype selectivity is proposed, based on the recently developed concept of inverse agonism.

  DOI：

  10.1016/s0223-5234(97)83285-0

文献信息

• Therapeutic compositions for diabetic symmetrical polyneuropathy
  申请人：Fernyhough Paul

  公开号：US10307428B2

  公开（公告）日：2019-06-04

  Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

  用于治疗糖尿病对称性多发性神经病变的组合物，该组合物包括：有效量的毒蕈碱乙酰胆碱受体拮抗剂，例如哌仑西平、替氮平、阿托品或其衍生物或其盐或其类似物或其衍生物，以及药理学上可接受的载体。该组合物可以注射，也可以局部使用，还可以口服。合适的局部组合物可包括乳液、膏霜、凝胶或粘稠液体。毒蕈碱乙酰胆碱受体拮抗剂可以是毒蕈碱乙酰胆碱受体拮抗剂盐或毒蕈碱乙酰胆碱受体拮抗剂衍生物或毒蕈碱乙酰胆碱受体拮抗剂类似物。
• THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY
  申请人：Fernyhough Paul

  公开号：US20130267506A1

  公开（公告）日：2013-10-10

  Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.
• TREATMENTS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY
  申请人：University of Manitoba

  公开号：US20190046540A1

  公开（公告）日：2019-02-14

  Treatments for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof. The treatments includes administration of compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.
• [EN] THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY<br/>[FR] COMPOSITIONS THÉRAPEUTIQUES POUR UNE POLYNEUROPATHIE DIABÉTIQUE SYMÉTRIQUE
  申请人：UNIV MANITOBA

  公开号：WO2012055018A1

  公开（公告）日：2012-05-03

  Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.
• Differential analgesic activity of the enantiomers of atropine derivatives does not correlate with their muscarinic subtype selectivity
  作者：S Dei、A Bartolini、C Bellucci、C Ghelardini、F Gualtieri、D Manetti、M.N. Romanelli、S Scapecchi、E Teodori

  DOI：10.1016/s0223-5234(97)83285-0

  日期：1997.7

  The enantiomers of several tropic and p-substituted tropic acid esters related to atropine obtained by esterification under non-racemizing conditions after resolution of the corresponding racemic acids [(+)- and (-)-18, (+)- and (-)-19] are reported. They were tested in vitro on muscarinic subtype receptors and in vivo for their analgesic activity on mice. As in the case of the lead compound, R-(+)-hyoscyamine, these substances show enantioselectivity in analgesic tests, the eutomers being the R-(+) or R-(+)-p-substituted tropic acid derivatives. However, this property, which is a consequence of increased central release of ACh, seems unrelated to muscarinic subtype selectivity insofar as the compounds are unable to discriminate muscarinic subtype receptors. A possible explanation of these results which does not involve subtype selectivity is proposed, based on the recently developed concept of inverse agonism.